Raymond James Financial’s Ascendis Pharma A/S ASND Stock Holding History

Raymond James Financial’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.84M	Sell	6,901 -1,753	-20%	-$409K	﹤0.01%	3544
2026 Q1	$1.98M	Buy	8,654 +1,992	+30%	+$447K	﹤0.01%	3370
2025 Q4	$1.42M	Buy	6,662 +3,393	+104%	+$701K	﹤0.01%	3538
2025 Q3	$650K	Buy	3,269 +1,967	+151%	+$367K	﹤0.01%	3960
2025 Q2	$225K	Sell	1,302 -4,042	-76%	-$658K	﹤0.01%	4453
2025 Q1	$833K	Buy	+5,344	New	+$763K	﹤0.01%	3614

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Raymond James Financial's ASND Position: Q2 2026 in Review

Raymond James Financial reduced its Ascendis Pharma A/S (ASND) stake by 20% in Q2 2026, selling an estimated $409K and leaving 6,901 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3544.

Raymond James Financial first reported a position in ASND in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.98M in Q1 2026. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Raymond James Financial held 6,901 shares of Ascendis Pharma A/S worth $1.84M as of Q2 2026.
Raymond James Financial sold 1,753 Ascendis Pharma A/S shares in Q2 2026, an estimated $409K.
Ascendis Pharma A/S made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3544 holding.
Raymond James Financial first reported a position in Ascendis Pharma A/S in Q1 2025 and has held it in 6 quarters since.
Raymond James Financial's Ascendis Pharma A/S position peaked at $1.98M in Q1 2026.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.